For many pathologies such as cancer or neurological disorders, it has been found that Histone Deacetylase (HDAC) activity is disrupted, making them promising targets for drug development. Scientists need access to a broade range of products ( Active Enzyme, inhibitors/activators, Biochemical screening assays…), to simplify their research and identification of HDAC inhibitors.
As mentioned in a previous post the DAX Biochips from AIM Biotech are an innovative and versatile microfluidic platform, allowing researchers to more easily develop 3D cell culture models, to work as close as possible to what occurs in the human body, but under in-vitro conditions.
Due to its innovative structure (as seen in this general AIM Chips flyer), a broad range of applications have already been validated on this model (Cellular Migration-Invasion Analysis / Angiogenesis studies / Metstasis Modeling System), but what’s new is that now Immunotherapy and T-Cell Therapy studies can be performed on this technology.
Over the last several years, the Immune System has appeared as a central, priority target to fight cancer and various other diseases. Currently, in cancer treatment most of the Immunotherapeutic successes, are molecules developed to modulate and restore immune response by targeting critical Immune Checkpoints.
Some of them can activate T Cells, and on the opposite, some can inhibit this response against cancer cells, such as PD-1 and CTLA4, two of the most studied Immune Checkpoints. The majority of the popular molecules approved in Immunotherapy which have led to clinical benefits, are antibodies inhibiting immune checkpoint activities, such for PD1 with nivolumab and pembrolizumab, or CTLA4 with ipilumab.
As a regulator of the immune system, Immune checkpoints appear to be privileged targets In Drug Discovery and Immunotherapy research. Indeed, promising molecules tested in clinical trials and approved are giving new hope for cancer treatment. Beyond checkpoint receptors, the Enzymatic pathway also regulates the immune system and provides additional targets for Drug Development, and may increase the chances of clinical success in Cancer treatment.
In addition to already developed Immune Checkpoint Reporter cell lines (as introduced in my previous post), BPS Bioscience also provide tools to study the enzymatic pathway, such as the tryptophan catabolism pathway controlled by IDO1: The IDO / TDO pathway.
Most popular posts
- HeLa cells: Origin of this important cell line in life science research
- From RUO to IVD - the acronym guide to reagents' intended use
- Differentiate between K48- and K63-specific Ubiquitination
- Differentiate between Apoptosis, Necroptosis, Autophagy & Ferroptosis
- How to choose the perfect buffer to get a pure, stabilised, functional protein